Eraxis Related Published Studies
Well-designed clinical trials related to Eraxis (Anidulafungin)
Anidulafungin compared with fluconazole for treatment of candidemia and other
forms of invasive candidiasis caused by Candida albicans: a multivariate analysis
of factors associated with improved outcome. [2011]
Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. [2009.12]
Anidulafungin in the treatment of invasive fungal infections. [2008.02]
Anidulafungin versus fluconazole for invasive candidiasis. [2007.06.14]
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. [2005.12]
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. [2004.09.15]
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. [2004.06]
Other research related to Eraxis (Anidulafungin)
Pharmacokinetics of anidulafungin in critically ill patients with
candidemia/invasive candidiasis. [2013]
Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult
patients with fungal infections. [2013]
Austrian clinical practice with anidulafungin in 2008: a multicenter survey. [2011.10]
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. [2011.09.30]
Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. [2011.08]
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. [2011.08]
Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. [2011.06]
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. [2011.05]
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema. [2011.05]
Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro? [2011.05]
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. [2011.04.28]
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature. [2011.04.28]
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. [2011.04.28]
Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. [2011.04]
Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? [2011.03]
Anidulafungin for the treatment of invasive candidiasis. [2011.03]
In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. [2011.03]
FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. [2011.03]
Clinical experience of anidulafungin for the treatment of patients with documented candidemia. [2010.12]
Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. [2010.10]
In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. [2010.10]
[Anidulafungin: a new therapeutic option in systemic candidiasis]. [2010.08]
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial. [2010.07]
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. [2010.07]
Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. [2010.04]
Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. [2009.11]
Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. [2009.09.21]
Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination. [2009.09]
Anidulafungin treatment of candidal central nervous system infection in a murine model. [2009.08]
Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. [2009.06]
Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. [2009.05]
Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. [2009.04]
In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. [2009.03]
Pharmacology and antifungal properties of anidulafungin, a new echinocandin. [2009.01]
Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. [2009]
Anidulafungin, a new echinocandin: effectiveness and tolerability. [2009]
Anidulafungin, a new echinocandin: in vitro activity. [2009]
[Potential of anidulafungin in combined therapy] [2008.12]
[Potential of anidulafungin in hematological patients] [2008.12]
[Role of anidulafungin in critically ill patients] [2008.12]
[Role of anidulafungin in solid organ transplant recipients] [2008.12]
[Current treatment of candidemia. Role of anidulafungin] [2008.12]
Anidulafungin: a novel echinocandin for candida infections. [2008.12]
Anidulafungin in the treatment of patients with invasive candidiasis. [2008.11]
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. [2008.10]
Anidulafungin: a drug evaluation of a new echinocandin. [2008.09]
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. [2008.08]
A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. [2008.07.01]
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. [2008.07]
Pharmacokinetics and tissue distribution of anidulafungin in rats. [2008.07]
[Anidulafungin] [2008.06]
[The role of anidulafungin therapy in solid organ transplant recipients] [2008.06]
[Anidulafungin: experimental therapy of fungal infections in animal models] [2008.06]
[Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis] [2008.06]
[Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin] [2008.06]
[Anidulafungin: a new echinocandin for the treatment of mycosis] [2008.06]
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. [2008.02]
Early clinical experience with anidulafungin at a large tertiary care medical center. [2008.01]
A review of the new antifungals: posaconazole, micafungin, and anidulafungin. [2007.12]
Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases. [2007.11]
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. [2007.07]
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. [2007.04]
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. [2007.03]
Anidulafungin: a new echinocandin for candidal infections. [2007.02]
Anidulafungin--state of affairs from a clinical perspective. [2007]
The safety of anidulafungin. [2006.11]
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. [2006.11]
Anidulafungin: a new echinocandin for the treatment of fungal infections. [2006.08]
Anidulafungin: a novel echinocandin. [2006.07.15]
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. [2006.02]
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. [2006.02]
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. [2005.11]
Anidulafungin: a new echinocandin with a novel profile. [2005.06]
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. [2005.02]
Anidulafungin: review of a new echinocandin antifungal agent. [2004.08]
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. [2004.06]
Anidulafungin. [2004]
Anidulafungin Vicuron. [2003.10]
Other possibly related research studies
A comparative evaluation of properties and clinical efficacy of the echinocandins. [2007.07]
Serum differentially alters the antifungal properties of echinocandin drugs. [2007.06]
The echinocandins. [2007.03]
New drugs 07, part I. [2007.02]
Echinocandins in the management of invasive fungal infections, Part 2. [2006.10.01]
Echinocandin antifungals: review and update. [2006.04]
Echinocandins: role in antifungal therapy, 2005. [2005.08]
Antifungal agents in children. [2005.06]
The use of topical therapies to treat onychomycosis. [2003.07]
Clinical efficacy of echinocandin antifungals. [2001.12]
The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? [2001.11]
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. [2001.02]
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. [2000.12]
New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. [2000]
Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. [2000.02]
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. [1999.09]
|
